IL1B and diabetes mellitus: Thus given inflammasome activation can impair several metabolically relevant signaling proteins such as Sirt1, additional studies are required to test whether specific inflammasome or caspase-1 inhibitors offer better therapeutic alternatives than IL-1β inhibition as treatment for diabetes.